Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|July 24, 2013
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalitiesVictor H Jimenez-Zepeda, Wee Joo Chng, Roelandt F J Schop, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic ReviewJessie Luo, Nizar J Bahlis, Denise Chan, et al.
Canadian Journal of Kidney Health and Disease|February 24, 2025
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 YearsChunpeng Nie, Holly Lee, Kim Cheema, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2011
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survivalVictor H Jimenez-Zepeda, Joseph Mikhael, Andrew Winter, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2020
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival OutcomesCarolina Diaz-Pallares, Holly Lee, Joanne Luider, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|September 8, 2021
Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian CenterVictor H Jimenez-Zepeda, Patrick Yau, Douglas Stewart, et al.
British Journal of Haematology|August 23, 2014
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myelomaDonna E Reece, Esther Masih-Khan, Eshetu G Atenafu, et al.
Blood|February 15, 2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisJoseph R Mikhael, Steven R Schuster, Victor H Jimenez-Zepeda, et al.
Transplantation|June 30, 2011
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplantsVictor H Jimenez-Zepeda, Raymond L Heilman, Rodney A Engel, et al.
Pageof 8